Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
EClinicalMedicine ; 27: 100538, 2020 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-33150319

RESUMO

BACKGROUND: Psilocybin therapy has shown promise as a rapid-acting treatment for depression, anxiety, and demoralization in patients with serious medical illness (e.g., cancer) when paired with individual psychotherapy. This study assessed the safety and feasibility of psilocybin-assisted group therapy for demoralization in older long-term AIDS survivor (OLTAS) men, a population with a high degree of demoralization and traumatic loss. METHODS: Self-identified gay men OLTAS with moderate-to-severe demoralization (Demoralization Scale-II ≥8) were recruited from the community of a major US city for a single-site open-label study of psilocybin-assisted group therapy comprising 8-10 group therapy visits and one psilocybin administration visit (0·3-0·36 mg/kg po). Primary outcomes were rate and severity of adverse events, and participant recruitment and retention. The primary clinical outcome was change in mean demoralization from baseline to end-of-treatment and to 3-month follow-up assessed with a two-way repeated measures ANOVA. Trial registration: Clinicaltrials.gov (NCT02950467). FINDINGS: From 17 July 2017 to 16 January 2019, 18 participants (mean age 59·2 years (SD 4·4)) were enrolled, administered group therapy and psilocybin, and included in intent-to-treat analyses. We detected zero serious adverse reactions and two unexpected adverse reactions to psilocybin; seven participants experienced self-limited, severe expected adverse reactions. We detected a clinically meaningful change in demoralization from baseline to 3-month follow-up (mean difference -5·78 [SD 6·01], ηp 2 = 0·47, 90% CI 0·21-0·60). INTERPRETATION: We demonstrated the feasibility, relative safety, and potential efficacy of psilocybin-assisted group therapy for demoralization in OLTAS. Groups may be an effective and efficient means of delivering psychotherapy pre- and post-psilocybin to patients with complex medical and psychiatric needs. FUNDING: Carey Turnbull, Heffter Research Institute, NIMH R25 MH060482, NIH UL1 TR001872, River Styx Foundation, Saisei Foundation, Sarlo Foundation, Stupski Foundation, Usona Institute, US Department of Veterans Affairs (Advanced Neurosciences Fellowship and IK2CX001495).

2.
Psychodyn Psychiatry ; 48(3): 271-294, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32996850

RESUMO

The complexity, uncertainty and charged nature of climate change make it a unique stressor that is irreconcilable at an individual level. This experience of impossibility leads to splitting of reactions into polarities, or dialectics, which must be contained to reduce climate distress and held open for generative use towards climate adaptation. We present a dynamic model for addressing climate change material within psychotherapy, wherein these climate dialectics are identified, explored, and held open. Clinical vignettes* illustrate therapeutic work with the particular climate dialectics of Climate Reality-Social Reality, Individual Agency-Collective Agency, Hope-Hopelessness, Certainty-Uncertainty, and Nature as Comfort-Nature as Threat. Situations of climate anxiety, solastalgia, disavowal, and the climate dismissive patient are addressed, as is the therapeutic use of the wordlessness that accompanies our relationship with the natural world. We explore and emphasize how a focus on the containment and transformation of climate anxiety, rather than on its reduction, assists in aligning with new realities and in the reduction of distress. Use of a developmental stage metaphor, attention to climate-specific counter-transference enactments, and emphasis on authentic action are central to this process.


Assuntos
Mudança Climática , Esperança , Relações Interpessoais , Psicoterapia , Ansiedade/psicologia , Terapia do Comportamento Dialético , Humanos
3.
J Psychoactive Drugs ; 51(2): 174-188, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30950777

RESUMO

Contemporary research with classic psychedelic drugs (e.g., lysergic acid diethylamide (LSD) and psilocybin) is indebted to the twentieth-century researchers and clinicians who generated valuable clinical knowledge of these substances through experimentation. Several recent reviews that highlight the contributions of this early literature have focused on psychedelic-assisted individual psychotherapy modalities. None have attempted to systematically identify and compile experimental studies of psychedelic-assisted group therapy. In therapeutic settings, psychedelics were often used to enhance group therapy for a variety of populations and clinical indications. We report on the results of a systematic review of the published literature in English and Spanish on psychedelic-assisted group therapies. Publications are characterized by their clinical approach, experimental method, and clinical outcomes. Given the renewed interest in the clinical use of psychedelic medicines, this review aims to stimulate hypotheses to be tested in future research on psychedelic-assisted psychotherapy, group process, and interpersonal functioning.


Assuntos
Alucinógenos/administração & dosagem , Psicoterapia de Grupo/métodos , Psicoterapia/métodos , Humanos , Dietilamida do Ácido Lisérgico/administração & dosagem , Psilocibina/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...